

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

May 29, 2026

To The Manager, Listing Department National Stock Exchange of India Limited Plot No. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai -400 051 Symbol: CONCORDBIO	To General Manager, Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 543960
--	--

Sub.: Outcome of Board Meeting held today i.e. Friday, May 29, 2026 - Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") as amended from time to time.

Dear Sir/ Ma'am,

With reference to the intimation of Board meeting submitted on May 23, 2026, we would like to inform you that the Board of Directors of the Company, at its meeting held today i.e. Friday, May 29, 2026, has inter-alia considered and approved following;

1. AUDITED FINANCIAL RESULTS

On review and recommendation of Audit Committee of the Company, the Board approved audited Standalone and Consolidated Financial Results for the fourth quarter and financial year ended on March 31, 2026.

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, we enclose herewith the audited Standalone and Consolidated Financial Results of the Company for the fourth quarter and financial ended on March 31, 2026, along with the Audit Report with Unmodified Opinion issued by M/s. BSR & Co. LLP, the Statutory Auditors.

2. FINANCIAL STATEMENT:

The Board has approved the Standalone as well as Consolidated Audited Financial Statement for the financial year ended on March 31, 2026.

3. BOARD'S REPORT:

The Board of Directors of the Company has also approved the Director's report for the financial year ended on March 31, 2026

4. DIVIDEND

The Board has recommended Dividend of Rs. 7.55 per Equity Share of face value of Re. 1 each fully paid up for the Financial Year 2025-26, subject to approval by shareholders of the Company at the ensuing AGM.

The Board has fixed July 24, 2026 as record date for the purpose of identifying the shareholders to whom dividend is to be paid.

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

5. APPOINTMENT OF INTERNAL AND COST AUDITORS

On recommendation of Audit Committee of the Company the Board has approved appointment of:

- a. M/s. Manubhai & Shah LLP as Internal Auditor of the Company for the F.Y. 2026-27
- b. M/s. Dalwadi & Associates as a Cost Auditor of the Company for the F.Y. 2026-27.

Details pertaining to SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 read with Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on July 11, 2023 and last updated on January 30, 2026 is enclosed herewith as **Annexure – A and Annexure-B**.

6. APPOINTMENT OF DIRECTORS

On the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company appointed Mrs. Ekta Gupta as an Additional Independent Director of the Company.

Details pertaining to SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 read with Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on July 11, 2023 and last updated on January 30, 2026 is enclosed herewith **Annexure-C**.

The Board Meeting commenced at 03:00 P.M. and concluded at 04:24 P.M.

This is for your information and records.

For Concord Biotech Limited

Paritosh Trivedi
Company Secretary and Compliance Officer
ACS 63623

Encl : As above

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

To The Manager, Listing Department National Stock Exchange of India Limited Plot No. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai -400 051 Symbol: CONCORDBIO	To General Manager, Listing Department BSE Limited Phiroze Jeejabhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 543960
--	---

Dear Sir/Madam,

Subject: Declaration pursuant to Regulation 33(3)(d) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

With reference to above, we hereby confirm that M/s. BSR & Co. LLP, the Statutory Auditor of the Company, have issued Audit Reports with unmodified opinion on the Standalone as well as Consolidated Audited Financial Results of the Company for the Financial Year ended March 31, 2026.

We request you to kindly take the above information on record and oblige.

Thanking you,

For Concord Biotech Limited

SUDHIR VAID
CHAIRMAN & MANAGING DIRECTOR
DIN: 00055967

- A.** Statement on Deviation or Variation for Proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement etc. - **Not Applicable**
- B.** Format for Disclosing Outstanding Default on Loans and Debt Securities — **Not Applicable, No Default**

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

Annexure-A

APPOINTMENT OF INTERNAL AUDITOR:

Sl. No	Particulars Details	Particulars Details
1.	Name of the Internal Auditor	M/s. Manubhai & Shah LLP
2.	Reason for change:	Appointment
3.	Term of Appointment:	Financial year 2026-27
4.	Brief Profile:	M/s. Manubhai & Shah LLP, Chartered Accountants (Firm Registration No. 106041W), has its head office in Ahmedabad and branch offices in Mumbai, New Delhi, Rajkot, Jamnagar, Vadodara, Udaipur, Gandhinagar, and Indore. The firm offers a comprehensive range of professional services to clients across the globe and is actively engaged in the audit of large corporates operating across diverse industry sectors.
5.	Disclosure of relationships between director	Not related to any of the Directors of the Company

Annexure-B

APPOINTMENT OF COST AUDITOR:

Sl. No	Particulars Details	Particulars Details
1.	Name of the Cost Auditor	M/s. Dalwadi & Associates
2.	Reason for change:	Appointment
3.	Term of Appointment:	Financial year 2026-27
4.	Brief Profile:	M/s. Dalwadi & Associates is a partnership firm based in Ahmedabad, bearing Firm Registration No. 000338. The firm possesses extensive experience in the fields of cost accounting and audit, and provides specialized services in Cost Management, design and implementation of Management Information Systems (MIS), statutory and voluntary cost audits, cost certification, and general management consultancy for leading manufacturing and service industries.
5.	Disclosure of relationships between director	Not related to any of the Directors of the Company

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

Annexure-C

APPOINTMENT OF DIRECTORS:

Sl. No	Particulars	Details
1.	Name of the Director	Mrs. Ekta Gupta
2.	Reason for change	Appointment
3.	Date of appointment & Term of appointment	Appointment as an Additional Independent Director with effect from June 01, 2026 for a term of 5 consecutive years, subject to approval of shareholders.
4.	Brief Profile	<p>Mrs. Ekta Gupta is a seasoned strategic leader, entrepreneur, and governance professional with extensive experience across finance, hospitality, education, and manufacturing sectors.</p> <p>She holds an MBA in Finance from Cardiff University and a B.Com (Hons) from Lady Shri Ram College, Delhi.</p> <p>Mrs. Ekta Gupta currently serves as Director - Sanghi Polymers Private Limited. She began her career in finance, including roles with Deutsche Bank and Financial Markets, before transitioning into leadership roles across business and social enterprises.</p> <p>Mrs. Ekta Gupta brings a combination of financial expertise, governance experience, entrepreneurial vision, and a strong commitment to community development, making her well-suited for Board of the organization.</p>
5.	Disclosure of relationships between directors	Not related to any of the Directors of the Company.
6.	Shareholding in the company, if any	NIL
7.	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/ 14/ 2018-19 and the National Stock Exchange of India Ltd with ref. no. NSE/ CML/ 2018/ 24, dated 20th June, 2018	N.A.

Independent Auditor's Report

To the Board of Directors of Concord Biotech Limited

Report on the audit of the Standalone Annual Financial Results

Opinion

We have audited the accompanying standalone annual financial results of Concord Biotech Limited (hereinafter referred to as the "Company") for the year ended 31 March 2026, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financial results:

- a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information for the year ended 31 March 2026.


Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion on the standalone annual financial results.

Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and



Independent Auditor's Report (Continued)

Concord Biotech Limited

presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results


Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the standalone annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Independent Auditor's Report (Continued)

Concord Biotech Limited

Other Matter

The standalone annual financial results include the results for the quarter ended 31 March 2026 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022



Rupen Shah

Partner

Ahmedabad

29 May 2026

Membership No.: 116240

UDIN:26116240MHWGEQ6309

CONCORD BIOTECH LIMITED



B-1601-1602, B-Wing, Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat.
Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440
E-mail : complianceofficer@concordbiotech.com

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

(Rs. in lakhs except per share data)

Sr. No.	Particulars	Quarter Ended			Year Ended	
		31-Mar-26 (Refer Note 2)	31-Dec-25 (Unaudited)	31-Mar-25 (Refer Note 2)	31-Mar-26 (Audited)	31-Mar-25 (Audited)
1	Income					
a	Revenue from operations	32,589.20	27,813.39	42,988.38	1,05,507.10	1,20,008.69
b	Other income	1,554.17	1,008.22	938.40	5,273.06	4,444.67
	Total Income	34,143.37	28,821.61	43,926.78	1,10,780.16	1,24,453.36
2	Expenses					
a	Cost of materials consumed	7,054.09	6,659.28	8,026.88	25,434.78	26,431.26
b	Purchase of stock-in-trade	1,567.01	2,006.71	1,031.85	6,222.86	5,598.72
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(53.57)	(2,049.51)	3,791.02	(7,061.49)	(1,478.67)
d	Employee benefits expense	4,501.87	4,408.72	3,896.57	17,018.60	13,893.36
e	Finance costs	5.84	5.84	9.55	23.40	52.93
f	Depreciation and amortisation expense	1,948.67	1,867.25	1,461.66	7,432.51	5,437.35
g	Other expenses					
	Power and fuel	2,975.97	2,843.66	2,933.73	11,619.93	11,223.02
	Others	4,305.73	3,722.41	4,266.06	14,618.85	13,707.85
	Total expenses	22,305.61	19,464.36	25,417.32	75,309.44	74,865.82
3	Profit before exceptional items and tax (1-2)	11,837.76	9,357.25	18,509.46	35,470.72	49,587.54
4	Exceptional Items:					
	Statutory impact of new labour codes (refer note 3)	-	327.54	-	327.54	-
5	Profit before tax (3-4)	11,837.76	9,029.71	18,509.46	35,143.18	49,587.54
6	Tax expenses:					
a	Current tax	2,864.81	2,156.83	4,181.53	8,629.09	11,896.14
b	Deferred tax	(29.26)	94.61	134.17	187.42	394.96
	Total tax expenses	2,835.55	2,251.44	4,315.70	8,816.51	12,291.10
7	Profit after tax for the period/year (5-6)	9,002.21	6,778.27	14,193.76	26,326.67	37,296.44
8	Other comprehensive income (net of tax)					
	Items that will not be reclassified to profit or loss					
a	Re-measurement gain/ (loss) on defined benefit plans	(68.75)	(63.44)	21.37	(162.24)	(56.98)
b	Income tax relating to re-measurement gain/ (loss) on defined benefit plans	17.30	15.97	(5.38)	40.83	14.34
c	Fair value changes on equity investments through OCI	1,685.42	2,748.13	978.22	6,687.09	854.62
d	Income tax relating to fair value changes on equity investments through OCI	(272.63)	(392.98)	(246.20)	(987.87)	(215.09)
	Other comprehensive income for the period/year	1,361.34	2,307.68	748.01	5,577.81	596.89
9	Total comprehensive income for the period/year (7+8)	10,363.55	9,085.95	14,941.77	31,904.48	37,893.33
10	Paid-up equity share capital (face value of Rs. 1/- each)	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16
11	Other equity				2,00,929.01	1,80,218.46
12	Earnings per share					
	Basic and diluted (in Rs.) (not annualised for the quarter)	8.60	6.48	13.57	25.17	35.65

Refer notes to the audited standalone financial results




CONCORD BIOTECH LIMITED


B-1601-1602, B-Wing, Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat.
Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440
E-mail : complianceofficer@concordbiotech.com

Notes to the statement of audited standalone financial results for the quarter and year ended March 31, 2026 :

1. The above standalone financial results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on May 29, 2026. The Statutory Auditors of the company have carried out audit of the said results.
2. The figures for the quarter ended March 31, 2026 and March 31, 2025 are the balancing figures between the audited figures with respect to the full financial year and the published unaudited year to date figures upto the third quarter ended December 31, 2025 and December 31, 2024 respectively, which were subjected to limited review.
3. On 21 November 2025, the Government of India notified four Labour Codes consolidating 29 existing labour laws. The Ministry of Labour and Employment has issued draft Central Rules and FAQs to facilitate assessment of the financial impact arising from these changes. Based on management's assessment including actuarial valuation, considering the best information available and ICAI guidance, the Company has recognised an incremental liability of ₹ 327.54 lakhs towards employee benefit obligation, primarily arising from the revised definition of wages under the New Labour Codes. Considering the event as regulatory-driven and non-recurring in nature, the impact of the same has been disclosed under exceptional items in the standalone results for the year ended 31 March 2026. The Company continues to monitor the notification of final Central/State rules and related clarifications and will evaluate and account for any additional impact in the period in which such rules are notified or clarifications issued.
4. The Company is engaged in the business of manufacturing and trading in pharmaceutical products. The entire business is considered as a single operating segment in terms of Indian Accounting Standard (Ind AS) 108 - "Operating Segment".
5. The above standalone financial results has been prepared in accordance with Indian Accounting Standards ("Ind AS") notified under Section 133 of the Companies Act, 2013 read together with Companies (Indian Accounting Standards) Rules, 2015 and in accordance with the guidelines issued by the Securities and Exchange Board of India ("SEBI").
6. Celliimune Biotech Private Limited that is incorporated on 15 January 2025 has been acquired by Concord Biotech Limited as on 2 April 2026. As at 31 March 2026 the company has invested ₹ 1.2 Lakhs for acquisition of shares out of total consideration of ₹ 66 Lakhs for this acquisition. Celliimune Biotech Private Limited became a wholly owned subsidiary on 2 April 2026.
7. The board of directors have recommended final dividend of ₹ 7.55/- per fully paid up equity share of ₹ 1/- each for financial year ended March 31, 2026 on outstanding paid up share capital of the company as on date, in its board meeting held on May 29, 2026, subject to approval of shareholders at ensuing annual general meeting of the Company.



Place: Ahmedabad
Date: 29th May 2026



For and on behalf of board of directors of
Concord Biotech Limited

Sudhir Vaid
Chairman & Managing Director
DIN: 00055967



CONCORD BIOTECH LIMITED

B-1601-1602, B-Wing, Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat.
 Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440
 E-mail : complianceofficer@concordbiotech.com

AUDITED STANDALONE STATEMENT OF ASSETS & LIABILITIES

(₹ in Lakhs)

Particulars	As at 31 March 2026	As at 31 March 2025
Assets		
I. Non-current assets		
(a) Property, plant and equipment	78,563.34	79,180.50
(b) Capital work-in-progress	7,815.92	5,013.10
(c) Intangible assets	24.58	59.61
(d) Right-of use assets	53.51	228.43
(e) Intangible assets under development	116.51	52.60
(f) Financial assets		
(i) Investments	8,562.52	1,865.42
(ii) Other Financial Assets	2,120.45	2,056.41
(g) Other non-current assets	1,591.53	1,260.07
(h) Income tax assets (Net)	283.81	177.66
Total non-current assets (A)	99,132.17	89,893.80
II. Current assets		
(a) Inventories	32,568.80	23,966.72
(b) Financial assets		
(i) Investments	40,206.37	31,654.48
(ii) Trade receivables	46,060.15	52,165.15
(iii) Cash and cash equivalents	788.89	90.45
(iv) Bank balances other than (iii) above	139.30	27.86
(v) Other Financial Assets	2,529.66	4,083.19
(c) Other Current assets	2,228.44	1,536.37
Total current assets (B)	1,24,521.61	1,13,524.22
TOTAL ASSETS (A) + (B)	2,23,653.78	2,03,418.02
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	1,046.16	1,046.16
(b) Other equity	2,00,929.01	1,80,218.46
Total equity (A)	2,01,975.17	1,81,264.62
LIABILITIES		
I. Non-current liabilities		
(a) Financial liabilities		
(i) Lease liabilities	45.55	62.98
(b) Provisions	371.97	281.99
(c) Deferred tax liabilities (net)	4,536.62	3,402.17
Total non-current liabilities (B)	4,954.14	3,747.14
II. Current liabilities		
(a) Financial liabilities		
(i) Borrowings	-	38.11
(ii) Lease liabilities	17.43	195.84
(iii) Trade payables		
Total outstanding dues of micro enterprises and small enterprises	1,474.95	595.24
Total outstanding dues of creditors other than micro enterprises and small enterprises	8,643.23	10,708.74
(iv) Other Financial Liabilities	4,232.53	4,169.79
(b) Provisions	1,123.43	554.00
(c) Other current liabilities	1,231.92	1,131.86
(d) Current tax liabilities (net)	0.98	1,012.68
Total current liabilities (C)	16,724.47	18,406.26
Total Liabilities (D)	21,678.61	22,153.40
TOTAL EQUITY AND LIABILITIES (A) + (D)	2,23,653.78	2,03,418.02



CONCORD BIOTECH LIMITED



B-1601-1602, B-Wing, Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat.
Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440
E-mail : complianceofficer@concordbiotech.com

AUDITED STANDALONE STATEMENT OF CASH FLOW

(₹ in Lakhs)

Particulars	For the Year ended 31 March 2026	For the Year ended 31 March 2025
(A) CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax as per Statement of Profit and Loss	35,143.18	49,587.54
Adjustment for:		
Depreciation and amortization expenses	7,432.51	5,437.35
Interest Income	(281.85)	(171.01)
Finance Cost	23.40	52.93
Interest Subsidy Income	-	(7.25)
Net gain/loss on termination of lease	-	(2.30)
(Reversal) /Provision for loss allowance	275.80	178.44
Excess provision no longer required written back	(347.54)	(273.24)
(Profit)/loss on sale/discard of Property, plant & equipment	(1.30)	22.47
Net gain on sale of investments	(1,153.13)	(1,360.57)
Net gain on financial assets measured at fair value through profit or loss	(959.64)	(865.80)
Net unrealised foreign exchange (gain) / loss	(1,094.81)	(129.24)
Operating Profit before Working Capital Changes	39,036.62	52,469.32
Working Capital Changes:		
(Increase)/Decrease in Inventories	(8,602.08)	(3,171.34)
Decrease/(Increase) in trade receivables	7,004.85	(17,078.77)
(Increase)/Decrease in other financial assets	(55.23)	(2,193.43)
(Increase)/Decrease in other assets	(808.86)	799.39
Increase/(Decrease) in provisions	497.17	193.21
Increase/(Decrease) in trade payables	(919.11)	2,208.91
(Decrease)/Increase in other financial liabilities	(128.83)	1,661.16
Increase in other liabilities	100.06	505.11
	(2,912.03)	(17,075.76)
Cash generated from operations	36,124.59	35,393.56
Direct Taxes paid (Net of Income Tax refund)	(9,746.94)	(10,941.87)
Net cash generated from operating activities	26,377.65	24,451.69
(B) CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Property, plant & equipment and Intangible Assets (including CWIP and capital advance)	(9,503.96)	(11,117.22)
Proceeds from disposal of Property, plant & equipment	10.03	19.90
Acquisition of subsidiary , net of cash	(2.28)	-
Investments in non current investments	(1.21)	-
Purchase of Current Investments	(94,680.00)	(86,993.89)
Proceeds from sale of Current Investment	88,240.88	80,137.07
Interest received	275.33	299.46
Proceeds from Bank Deposits (Net) (including margin money deposits)	-	2,387.74
Investment in Current deposits with banks (including margin money deposits)	(111.44)	(1,511.71)
Proceeds from Non current deposits with Bank (including margin money deposits)	1,544.72	780.00
Net cash used in investing activities	(14,227.93)	(15,998.65)
(C) CASH FLOW FROM FINANCING ACTIVITIES		
Repayment of current borrowings	(38.11)	(584.87)
Dividend Paid (net of TDS)	(11,193.93)	(9,153.92)
Interest Paid	-	(25.07)
Interest Subsidy Received	-	14.96
Principal Payment of Lease Liabilities	(195.84)	(89.66)
Interest paid on Lease Liabilities	(23.40)	(38.25)
Net cash used in financing activities	(11,451.28)	(9,876.80)
NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS (A)+(B)+(C)	698.44	(1,423.76)
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR	90.45	1,514.21
CASH AND CASH EQUIVALENTS AT END OF THE YEAR	788.89	90.45

Particulars	As at 31 March 2026	As at 31 March 2025
Cash on hand	2.24	1.89
Balance with Banks	786.65	88.56
Cash and cash equivalents	788.89	90.45



Independent Auditor's Report

To the Board of Directors of Concord Biotech Limited

Report on the audit of the Consolidated Annual Financial Results

Opinion

We have audited the accompanying consolidated annual financial results of Concord Biotech Limited (hereinafter referred to as the "Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), and its joint venture for the year ended 31 March 2026, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate audited financial results of the subsidiaries, the aforesaid consolidated annual financial results:

- include the annual financial results of the entities mentioned in Annexure I to the statement.
- are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of consolidated net profit and other comprehensive income and other financial information of the Group for the year ended 31 March 2026.


Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results* section of our report. We are independent of the Group, and its joint venture in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, along with the consideration of reports of the other auditors referred to in sub paragraph no. (a) of the "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion on the consolidated annual financial results.

Management's and Board of Directors' Responsibilities for the Consolidated Annual Financial Results

These consolidated annual financial results have been prepared on the basis of the consolidated annual financial statements.

The Holding Company's Management and the Board of Directors are responsible for the preparation and presentation of these consolidated annual financial results that give a true and fair view of the consolidated net profit/ loss and other comprehensive income and other financial information of the Group including its joint venture in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the



Independent Auditor's Report (Continued)

Concord Biotech Limited

Listing Regulations. The respective Management and Board of Directors of the companies included in the Group and the respective Management and Board of Directors of its joint venture are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated annual financial results by the Management and the Board of Directors of the Holding Company, as aforesaid.

In preparing the consolidated annual financial results, the respective Management and the Board of Directors of the companies included in the Group and the respective Management and Board of Directors of its joint venture are responsible for assessing the ability of each company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.


The respective Board of Directors of the companies included in the Group of its joint venture is responsible for overseeing the financial reporting process of each company.

Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the consolidated annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its joint venture to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated annual financial results



Independent Auditor's Report (Continued)

Concord Biotech Limited

including the disclosures, and whether the consolidated annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

- Obtain sufficient appropriate audit evidence regarding the financial statements of the entities within the Group and its joint venture to express an opinion on the consolidated annual financial results. We are responsible for the direction, supervision and performance of the audit of financial statements of such entity included in the consolidated annual financial results of which we are the independent auditor. For the other entities included in the consolidated annual financial results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in sub paragraph no. (a) of the "Other Matters" paragraph in this audit report.

We communicate with those charged with governance of the Holding Company, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular No CIR/CFD/CMD1/44/2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

Other Matter(s)

- a. The consolidated annual financial results include the audited financial information of two subsidiaries, whose financial information reflects total assets (before consolidation adjustments) of Rs. 1,037.43 lakhs as at 31 March 2026, total revenue (before consolidation adjustments) is Rs. 41.71 lakhs and total net (loss) after tax (before consolidation adjustments) of Rs. (694.69) lakhs and net cash inflows (before consolidation adjustments) of Rs. 429.72 lakhs for the year ended on that date, as considered in the consolidated annual financial results, which have been audited by their respective independent auditors. The independent auditor's report on financial information of these entities have been furnished to us by the management.

Our opinion on the consolidated annual financial results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.

Our opinion on the consolidated annual financial results is not modified in respect of the above matters with respect to our reliance on the work done and the report of the other auditors.

- b. The consolidated annual financial results include the Group's share of total net profit/(loss) after tax (before consolidation adjustments) of Rs. 33.92 lakhs for the year ended 31 March 2026, as considered in the consolidated annual financial results, in respect of one joint venture. This unaudited financial information has been furnished to us by the Board of Directors.

Our opinion on the consolidated annual financial results, in so far as it relates to the amounts and disclosures included in respect of joint venture is based solely on such financial information. In our opinion and according to the information and explanations given to us by the Board of Directors, this financial information is not material to the Group.

Our opinion on the consolidated annual financial results is not modified in respect of the above matter with respect to the financial information certified by the Board of Directors.

- c. The consolidated annual financial results include the results for the quarter ended 31 March 2026 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which



B S R & Co. LLP

Independent Auditor's Report (Continued)
Concord Biotech Limited

were subject to limited review by us.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022



Rupen Shah

Partner

Ahmedabad

29 May 2026

Membership No.: 116240

UDIN:26116240GCNTVD4232

Independent Auditor's Report (Continued)
Concord Biotech Limited

Annexure I

List of entities included in consolidated annual financial results.

Sr. No	Name of component	Relationship
1	Concord Biotech Limited	Holding Company
2	Concord Lifegen Limited	Wholly owned subsidiary
3	Stellon Biotech Inc.	Subsidiary
4	Concord Biotech Japan K.K.	Joint Venture



CONCORD BIOTECH LIMITED

B-1601-1602, B-Wing, Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440


E-mail : complianceofficer@concordbiotech.com

STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

(Rs. in lakhs except per share data)

Sr.No.	Particulars	Quarter Ended			Year Ended	
		31-Mar-26 (Refer Note 3)	31-Dec-25 (Unaudited)	31-Mar-25 (Refer Note 3)	31-Mar-26 (Audited)	31-Mar-25 (Audited)
1	Income					
a	Revenue from operations	32,607.96	27,776.60	42,988.38	1,05,489.07	1,20,008.69
b	Other income	1,534.94	997.62	938.40	5,235.53	4,444.67
	Total Income	34,142.90	28,774.22	43,926.78	1,10,724.60	1,24,453.36
2	Expenses					
a	Cost of materials consumed	7,054.09	6,659.28	8,026.88	25,434.78	26,431.26
b	Purchase of stock-in-trade	1,567.02	2,044.47	1,031.85	6,260.63	5,598.72
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(39.62)	(2,130.27)	3,791.02	(7,128.30)	(1,478.67)
d	Employee benefits expense	4,777.12	4,678.07	3,896.57	17,690.48	13,893.36
e	Finance costs	8.40	8.15	9.55	28.32	52.93
f	Depreciation and amortisation expense	1,954.39	1,874.69	1,461.66	7,445.86	5,437.35
g	Other expenses					
	Power and fuel	2,975.97	2,843.66	2,933.73	11,619.93	11,223.02
	Others	4,420.23	3,783.35	4,266.06	14,871.56	13,707.85
	Total Expenses	22,717.60	19,761.40	25,417.32	76,223.26	74,865.82
3	Profit before exceptional Items and tax (1-2)	11,425.30	9,012.82	18,509.46	34,501.34	49,587.54
4	Exceptional Items:					
	Statutory impact of new labour codes (refer note 5)	-	327.54	-	327.54	-
5	Profit before tax and share of profit of joint venture (3-4)	11,425.30	8,685.28	18,509.46	34,173.80	49,587.54
6	Share of profit / (loss) of joint venture (net of tax)	(17.76)	(69.69)	(155.04)	290.92	(132.21)
7	Profit before tax (5+6)	11,407.54	8,615.59	18,354.42	34,464.72	49,455.33
8	Tax expenses:					
a	Current tax	2,864.81	2,156.83	4,181.53	8,629.09	11,896.14
b	Deferred tax	(303.96)	94.61	134.17	(87.28)	394.96
	Total tax expenses	2,560.85	2,251.44	4,315.70	8,541.81	12,291.10
9	Profit after tax for the period/year (7-8)	8,846.69	6,364.15	14,038.72	25,922.91	37,164.23
10	Other comprehensive income (net of tax)					
	Items that will not be reclassified to profit or loss					
a	Re-measurement gain/ (loss) on defined benefit plans	(68.75)	(63.44)	21.37	(162.24)	(56.98)
b	Income tax relating to re-measurement gain/ (loss) on defined benefit plans	17.30	15.97	(5.38)	40.83	14.34
c	Fair value changes on equity investments through OCI	1,685.42	2,748.13	978.22	6,687.09	854.62
d	Income tax relating to fair value changes on equity investments through OCI	(272.63)	(392.98)	(246.20)	(987.87)	(215.09)
e	Items that will be reclassified to profit or loss					
	Foreign currency translation reserves	(35.01)	(12.95)	-	(53.45)	-
	Other comprehensive income for the period/year	1,326.33	2,294.73	748.01	5,524.36	596.89
11	Total comprehensive income for the period/year(9+10)	10,173.02	8,658.88	14,786.73	31,447.27	37,761.12
12	Profit for the period attributable to:					
	Owners of the company	8,879.05	6,447.66	14,038.72	26,090.59	37,164.23
	Non-controlling interest	(32.35)	(83.51)	-	(167.68)	-
	Profit for the period	8,846.70	6,364.15	14,038.72	25,922.91	37,164.23
13	Other comprehensive income for the period attributable to:					
	Owners of the company	1,335.09	2,297.97	748.01	5,537.72	596.89
	Non-controlling interest	(8.75)	(3.24)	-	(13.36)	-
	Other comprehensive income for the period	1,326.33	2,294.73	748.01	5,524.36	596.89
14	Total comprehensive income for the period attributable to:					
	Owners of the company	10,214.15	8,745.63	14,786.73	31,628.31	37,761.12
	Non-controlling interest	(41.11)	(86.75)	-	(181.04)	-
	Total comprehensive income for the period	10,173.04	8,658.88	14,786.73	31,447.27	37,761.12
15	Paid-up equity share capital (face value of Rs. 1/- each)	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16
16	Other equity				2,00,659.97	1,80,225.59
17	Earnings per share					
	Basic and diluted (In Rs.) (not annualised for the quarter)	8.46	6.08	13.42	24.78	35.52

Refer notes to the audited consolidated financial results



CONCORD BIOTECH LIMITED

B-1601-1602, B-Wing, Mondeal Heights, Iscon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat.
Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440
E-mail : complianceofficer@concordbiotech.com

Notes to the statement of audited consolidated financial results for the quarter and year ended March 31, 2026 :

1. The above consolidated financial results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on 29th May, 2026. The Statutory Auditors of the company have carried out audit of the said results.
2. The audited consolidated financial results of the Group include information of wholly owned subsidiary Concord Lifegen Limited (w.e.f 21st July 2025), subsidiary Stellon Biotech Inc. (w.e.f 1st July 2025) and joint venture Concord Biotech Japan K.K.
3. The figures for the quarter ended March 31, 2026 and March 31, 2025 are the balancing figures between the audited figures with respect to the full financial year and the published unaudited year to date figures upto the third quarter ended December 31, 2025 and December 31, 2024 respectively, which were subjected to limited review.
4. The Group is engaged in the business of manufacturing and trading in pharmaceutical products. The entire business is considered as a single operating segment in terms of Indian Accounting Standard (Ind AS) 108 - "Operating Segment".
5. On 21 November 2025, the Government of India notified four Labour Codes consolidating 29 existing labour laws. The Ministry of Labour and Employment has issued draft Central Rules and FAQs to facilitate assessment of the financial impact arising from these changes. Based on management's assessment including actuarial valuation, considering the best information available and ICAI guidance, the group has recognised an incremental liability of ₹ 327.54 lakhs towards employee benefit obligation, primarily arising from the revised definition of wages under the New Labour Codes. Considering the event as regulatory-driven and non-recurring in nature, the impact of the same has been disclosed under exceptional items in the consolidated results for the year ended 31 March 2026. The group continues to monitor the notification of final Central/State rules and related clarifications and will evaluate and account for any additional impact in the period in which such rules are notified or clarifications issued.
6. Cellimmune Biotech Private Limited that is incorporated on 15 January 2025 has been acquired by Concord Biotech Limited as on 2 April 2026. As at 31 March 2026 the company has invested ₹ 1.2 Lakhs for acquisition of shares out of total consideration of ₹ 66 Lakhs for this acquisition. Cellimmune Biotech Private Limited became a wholly owned subsidiary on 2 April 2026.
7. The above consolidated financial results has been prepared in accordance with Indian Accounting Standards ("Ind AS") notified under Section 133 of the Companies Act, 2013 read together with Companies (Indian Accounting Standards) Rules, 2015 and in accordance with the guidelines issued by the Securities and Exchange Board of India ("SEBI").



Place: Ahmedabad
Date: 29th May 2026



For and on behalf of board of directors of
Concord Biotech Limited


Sudhir Vaid
Chairman & Managing Director
DIN: 00055967



CONCORD BIOTECH LIMITED

B-1601-1602, B-Wing, Mondeal Heights, Iskon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat.
Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440
E-mail : complianceofficer@concordbiotech.com

AUDITED CONSOLIDATED STATEMENT OF ASSETS & LIABILITIES

(₹ in Lakhs)

Particulars	As at 31 March 2026	As at 31 March 2025
Assets		
I. Non-current assets		
(a) Property, plant and equipment	78,571.73	79,180.50
(b) Capital work-in-progress	7,815.92	5,013.10
(c) Intangible assets	25.97	59.61
(d) Right-of use assets	218.07	228.43
(e) Goodwill	39.63	-
(f) Intangible assets under development	116.51	52.60
(g) Investment accounted for using the equity method	364.57	73.65
(h) Financial assets		
(i) Investments	8,493.72	1,798.90
(ii) Other Financial Assets	646.42	2,056.41
(i) Other non-current assets	1,591.52	1,260.07
(j) Income tax assets (Net)	283.81	177.66
(k) Deferred tax assets (net)	293.66	
Total non-current assets (A)	98,461.53	89,900.93
II. Current assets		
(a) Inventories	32,635.61	23,966.72
(b) Financial assets		
(i) Investments	40,206.37	31,654.48
(ii) Trade receivables	46,019.71	52,165.15
(iii) Cash and cash equivalents	1,218.60	90.45
(iv) Bank balances other than (iii) above	139.30	27.86
(v) Other Financial Assets	2,524.01	4,083.19
(c) Other Current assets	2,267.59	1,536.37
Total current assets (B)	1,25,011.18	1,13,524.22
TOTAL ASSETS (A) + (B)	2,23,472.71	2,03,425.15
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	1,046.16	1,046.16
(b) Other equity	2,00,659.97	1,80,225.59
Equity attributable to owners of the company	2,01,706.13	1,81,271.75
(c) Non controlling Interest	(192.33)	-
Total equity (A)	2,01,513.80	1,81,271.75
LIABILITIES		
I. Non-current liabilities		
(a) Financial liabilities		
(i) Lease liabilities	143.34	62.98
(b) Provisions	371.97	281.99
(c) Deferred tax liabilities (net)	4,535.89	3,402.17
Total non-current liabilities (B)	5,051.20	3,747.14
II. Current liabilities		
(a) Financial liabilities		
(i) Borrowings	-	38.11
(ii) Lease liabilities	88.22	195.84
(iii) Trade payables		
Total outstanding dues of micro enterprises and small enterprises	1,474.95	595.24
Total outstanding dues of creditors other than micro enterprises and small enterprises	8,715.99	10,708.74
(iv) Other Financial Liabilities	4,270.41	4,169.79
(b) Provisions	1,123.43	554.00
(c) Other current liabilities	1,233.79	1,131.86
(d) Current tax liabilities (net)	0.92	1,012.68
Total current liabilities (C)	16,907.71	18,406.26
Total Liabilities (D)	21,958.91	22,153.40
TOTAL EQUITY AND LIABILITIES (A) + (D)	2,23,472.71	2,03,425.15



CONCORD BIOTECH LIMITED

B-1601-1602, B-Wing, Mondeal Heights, Iskon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

E-mail : complianceofficer@concordbiotech.com

AUDITED CONSOLIDATED STATEMENT OF CASH FLOW

(₹ in Lakhs)

Particulars	For the Year ended 31 March 2026	For the Year ended 31 March 2025
(A) CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax as per Statement of Profit and Loss	34,464.72	49,455.33
Adjustment for:		
Share of Loss/(profit) from Joint Venture	(290.92)	132.21
Depreciation and amortization expenses	7,445.86	5,437.35
Interest Income	(246.29)	(171.01)
Finance Cost	28.32	52.93
Interest Subsidy Income	-	(7.25)
Net gain/loss on termination of lease	-	(2.30)
Provision for expected credit loss	275.80	178.44
Excess provision no longer required written back	(347.54)	(273.24)
(Profit)/loss on sale/discard of Property, plant & equipment	(1.30)	22.47
Net gain on sale of investments	(1,153.13)	(1,360.57)
Net gain on financial assets measured at fair value through profit or loss	(959.64)	(865.80)
Net unrealised foreign exchange (gain) / loss	(1,094.81)	(129.24)
Operating Profit before Working Capital Changes	38,121.07	52,469.32
Working Capital Changes:		
(Increase)/Decrease in Inventories	(8,668.89)	(3,171.34)
Decrease/(Increase) in trade receivables	7,045.29	(17,078.77)
(Increase)/Decrease in other financial assets	1,424.45	(2,193.43)
(Increase)/Decrease in other assets	(849.30)	799.39
Increase/(Decrease) in provisions	497.17	193.21
Increase/(Decrease) in trade payables	(851.98)	2,208.91
(Decrease)/Increase in other financial liabilities	(90.95)	1,661.16
Increase in other liabilities	101.93	505.11
	(1,392.28)	(17,075.76)
Cash generated from operations	36,728.79	35,393.56
Direct Taxes paid (Net of Income Tax refund)	(10,040.66)	(10,941.87)
Net cash generated from operating activities	26,688.13	24,451.69
(B) CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Property, plant & equipment and Intangible Assets (including CWIP and capital advance)	(9,515.11)	(11,117.22)
Proceeds from disposal of Property, plant & equipment	10.03	19.90
Investments in non current investments	(1.21)	-
Purchase of Current Investments	(94,680.00)	(86,993.89)
Proceeds from sale of Current Investment	88,240.88	80,137.07
Interest received	239.77	299.46
Proceeds from Bank Deposits (Net) (including margin money deposits)	-	2,387.74
Investment in Current deposits with banks (including margin money deposits)	(111.44)	(1,511.71)
Proceeds from Non current deposits with Bank (including margin money deposits)	1,544.72	780.00
Net cash used in investing activities	(14,272.36)	(15,998.65)
(C) CASH FLOW FROM FINANCING ACTIVITIES		
Repayment of current borrowings	(38.11)	(584.87)
Dividend Paid (net of TDS)	(11,193.93)	(9,153.92)
Interest Paid	(0.12)	(25.07)
Interest Subsidy Received	-	14.96
Principal Payment of Lease Liabilities	(27.26)	(89.66)
Interest paid on Lease Liabilities	(28.20)	(38.25)
Net cash used in financing activities	(11,287.62)	(9,876.80)
NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS (A)+(B)+(C)	1,128.15	(1,423.76)
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR	90.45	1,514.21
CASH AND CASH EQUIVALENTS AT END OF THE YEAR	1,218.60	90.45

Particulars	As at 31 March 2026	As at 31 March 2025
Cash on hand	2.24	1.89
Balance with Banks	1,216.36	88.56
Cash and cash equivalents	1,218.60	90.45

